This study reveals the previously underappreciated roles of CD25 (IL-2 receptor subunit-α) in IL-2 biology and cancer immunotherapy and provides mechanistic insights into the rational design of more-effective IL-2-based therapeutic agents for cancer treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Abbas, A. K., Trotta, E., Simeonov, D. R., Marson, A. & Bluestone, J. A. Revisiting IL-2: biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018). A review article that presents the dual and opposing functions of IL-2.
Hernandez, R., Põder, J., LaPorte, K. M. & Malek, T. R. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat. Rev. Immunol. 22, 614–628 (2022). A review article summarizing the different approaches to engineering IL-2 analogs.
[No authors listed]. Bempeg failure unlikely to affect other IL2 drugs. Cancer Discov. 12, 1604–1605 (2022). This news-in-brief article reports the clinical failure of an engineered IL-2.
Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877–884 (2022). This paper reports a new method of neoantigen-specific T cell receptor prediction.
Gide, T. N. et al. Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1/Anti-CTLA-4 combined therapy. Cancer cell 35, 238–255 (2019). This paper reports predictive biomarkers of anti-PD-1 responses in patients with melanoma.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Wu, W. et al. IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells. Nat. Cancer https://doi.org/10.1038/s43018-023-00612-0 (2023).
Rights and permissions
About this article
Cite this article
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy. Nat Cancer 4, 1222–1223 (2023). https://doi.org/10.1038/s43018-023-00613-z
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s43018-023-00613-z
